Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.23 [1.05, 1.43]
Studies not reported
Moderate
Subjective participant assessment at 4 weeks; 755 participants(6 RCTs) · cervical dystonia
Botulinum toxin type A leads to higher subjective participant assessment at 4 weeks; 755 participants(6 RCTs) compared with placebo (high certainty).
1 finding from 1 review
RR 2.19 [1.78, 2.7]
Studies not reported
High
Cervical dystonia‐specific pain · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Tolerability assessed as dropouts at 4 to 6 weeks: 705 participants (5 RCTs) · cervical dystonia
Botulinum toxin type A leads to lower tolerability assessed as dropouts at 4 to 6 weeks: 705 participants… compared with placebo (high certainty).
1 finding from 1 review
RR 0.48 [0.32, 0.73]
Studies not reported
High
Health‐related quality of life · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Duration of effect 618 participants (5 RCTs) · cervical dystonia
It is very uncertain whether botulinum toxin type A changes duration of effect 618 participants (5 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Blepharospasm‐specific severity ( · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Adverse events (reported at any time) (2 RCT, 169 participants) · adults with blepharospasm
Botulinum toxin type A showed no clear difference in adverse events (reported at any time) (2 RCT, 169 participants) compared with placebo (low certainty).
1 finding from 1 review
RR 1.18 [0.87, 1.6]
Studies not reported
Low
Subjective evaluation of the treatments by participants · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
High
Frequency of blepharospasm‐specific involuntary movements ( · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Health‐related quality of life · adults with blepharospasm
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tolerability (number of dropouts; reported at any time) (2 RCT, 169 participants) · adults with blepharospasm
Botulinum toxin type A showed no clear difference in tolerability (number of dropouts; reported at any time) (2 RCT, 169… compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.44 [0.31, 6.79]
Studies not reported
Moderate
Duration of effect (when effects started to wane) · adults with blepharospasm
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Overall cervical dystonia improvement as · adults with cervical dystonia
1 finding from 1 review
Withdrawals due to adverse events · adults with cervical dystonia
Botulinum neurotoxin B showed no clear difference in proportion of withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Cervical dystonia‐specific pain · adults with cervical dystonia
1 finding from 1 review
Subjective change as assessed by the patient at week 4 · adults with cervical dystonia
1 finding from 1 review
Proportion of participants with adverse events · adults with cervical dystonia
It is very uncertain whether botulinum neurotoxin B changes proportion of participants with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dry mouth · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dry mouth compared with placebo (high certainty).
1 finding from 1 review
Dysphagia · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dysphagia compared with placebo (high certainty).
1 finding from 1 review